You are here

Practice Management

 - Female patient blood pressure

Older women who have undergone menopause are less likely than men of a similar age to die from coronary heart disease (CHD), according to a prospective cohort study of more than 30,000 residents of 10 Southern states.

 - Running

Half of the cardiovascular deaths in U.S. adults in 2009 and 2010 were due to modifiable risk factors such as elevated cholesterol, diabetes, hypertension, obesity and smoking, according to a cross-sectional analysis of a large survey.

 - Blood Pressure

Young adults with elevated levels of blood pressure were more likely to have left ventricular systolic and diastolic dysfunction in middle age, according to a prospective study that tracked people over 25 years.

 - Ebola red

Physicians are making a case for statins and ARBs as a treatment for Ebola patients. They are not proposing the combination of drugs is a cure or preventive but rather an aid in survival to give patients time to build up immunity to the virus.

 - cholesterol

Approximately half of Hispanic and Latino adults in the U.S. were unaware they had high cholesterol and fewer than one-third received treatment for the condition, according to a cohort study in four geographically diverse communities.


More Stories

Educating patients after stroke or TIA helps reduce emergency department arrival time

Providing patients with educational materials or an interactive intervention when they were discharged for stroke or transient ischemic attack (TIA) helped reduce the time they waited before heading to the emergency department following subsequent stroke, TIA or stroke-like symptoms.

Joint Commission outlines rules for Comprehensive Cardiac Centers

The Joint Commission unveiled proposed requirements for an optional advanced certification program for Comprehensive Cardiac Centers in accredited hospitals. The commission will accept comments through July 16.

FDA advisory panel members express concerns with PCSK9 inhibitors

On June 9 and 10, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended the approval of alirocumab and evolocumab to lower low-density lipoprotein cholesterol in patients. Two members of the committee who did not recommend approval for either drug spoke with Cardiovascular Business about their concerns.

TAVR program raises margin 350% by befriending rivals

Why swim with the sharks if you can float above them in uncontested waters? One medical center is taking a “Blue Ocean” approach to its transcatheter aortic valve replacement (TAVR) program after its success with a liver initiative netted $1.1 million and saved the healthcare system $54 million. 

Linking autonomy with accountability reaps rewards

Accountability and autonomy can go hand in hand. Citing a lesson learned from his military service, Christopher White, MD, showed that cardiologists at Ochsner earned autonomy through a program that made them accountable for resource use.

Novel oral anticoagulant use after stroke is increasing but still lags behind warfarin

Despite the approval of novel oral anticoagulants in recent years, nearly 90 percent of atrial fibrillation patients with ischemic stroke or transient ischemic attack receive warfarin, according to analysis of patients hospitalized between October 2010 and September 2012.

Minding MACRA

Is MACRA the new SGR? Thankfully not. But that doesn’t mean you can ignore it.

Proton pump inhibitors may increase risk for MI

Patients who take proton pump inhibitors (PPIs) may be at an increased risk for myocardial infarction (MI) and other cardiovascular outcomes, according to a data mining analysis. However, there was no association between the use of H2 blockers and MI or cardiovascular risk. H2 blockers are alternatives to PPIs in treating gastroesophageal reflux disease.

Cardiovascular network provides benefits beyond patient referrals

If the alliance between his health system in Texas and the Cleveland Clinic didn’t bring a single new patient through their doors, it would still be a victory, said Michael Mack, MD. “We’ve already received enough value that we view this as a success.”

FDA advisory panel recommends approval of second PCSK9 inhibitor in two days

An FDA advisory panel on June 10 recommended the approval of evolocumab, a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor intended to reduce low-density lipoprotein cholesterol and improve other lipids.

Higher symptom burden correlates with decreased quality of life but not risk of death in AF patients

An analysis of a large, nationwide registry of patients with atrial fibrillation has delivered some counterintuitive results that could signal a needed change in healthcare utilization for such patients.

Panel recommends FDA approve PCSK9 inhibitor alirocumab

The FDA’s advisory panel voted 13-3 in favor of alirocumab as an anticholesterol treatment, paving the way for what might become the first fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) in the U.S.

N.Y. center pays $18.8M to settle case about cardiology referrals

A New York medical center paid almost $19 million to settle a kickback case involving a cardiology practice. The charges alleged that the medical center improperly paid the practice for referrals and improperly submitted cost reports for cardiology fellows’ services.

FDA panel to review evolocumab for hyperlipidemia and other indications

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to vote on June 10 on the safety and efficacy of evolocumab, an injectable medication to treat hyperlipidemia, mixed dyslipidemia and homozygous familial hypercholesterolemia.

Statin and nonstatin lipid-lowering drug users show memory loss within 30 days

Within 30 days of first taking statin and nonstatin lipid-lowering drugs (LLDs), patients were more likely have memory loss compared with a group that was not treated with any LLDs, according to a retrospective cohort study. When comparing statin and nonstatin users, there was no difference in memory loss.

FDA panel to review PCSK9 inhibitor

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to vote June 9 on the safety and effectiveness of the monoclonal antibody alirocumab as a treatment for patients with hypercholesterolemia.

Chest-compression only CPR training improves survival after cardiac arrest

Japanese patients who received chest-compression only CPR after an out-of-hospital cardiac arrest had an increase in survival with a favorable neurologic outcome, according to a nationwide observational study.

Small is beautiful

The scientific sessions by the American College of Cardiology and the Transcatheter Cardiovascular Therapies (TCT) arguably are the big dogs in cardiology-related conferences. Many consider them “can’t miss” events, but smaller venues offer benefits as well.

Glucose control improves cardiovascular outcomes in military vets with type 2 diabetes

Long-term cardiovascular outcomes improved in U.S. military veterans with type 2 diabetes who received intensive glucose control, although their rate of overall survival was similar to patients who received standard therapy.

Nearly one-third of patients are nonadherent to medications after PCI

Nearly one-third of patients who underwent percutaneous coronary intervention (PCI) to treat myocardial infarction (MI) did not fully adhere to their prescribed medications six weeks after their MI, according to an analysis of a study at 216 U.S. hospitals.